LY2605541

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for LY2605541, covering 2014-10-21 to 2019-06-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes [Phase 1]